Akorn (AKRXQ) Stock Price, News & Analysis

Company Overview

Akorn, Inc. was a specialty pharmaceutical company focused on the development, manufacturing and marketing of generic and specialty prescription medicines. Its product portfolio included ophthalmic solutions and suspensions, injectable drugs, oral liquids, topical products and other dosage forms intended for use in hospitals, clinics and outpatient settings.

The company served customers primarily in the United States and supplied products through pharmaceutical distributors, wholesalers, pharmacies, healthcare providers and government channels. Akorn operated manufacturing and research facilities in the U.S. and pursued abbreviated new drug applications and other regulatory approvals for generic medicines.

Akorn experienced significant operational and financial challenges, including the termination of Fresenius SE's proposed acquisition in 2018. The company filed for Chapter 11 bankruptcy protection in 2020 and later emerged from restructuring, but subsequently entered Chapter 7 proceedings in 2023 and began winding down its operations. As a result, Akorn is no longer operating as an active pharmaceutical business in its former capacity.

Key Stats

• Today's Range: $0.03 to $0.03
• 50-Day Range: $0.03 to $0.03
• 52-Week Range: $0.01 to $5.40
• Volume: N/A
• Average Volume: 7.44 million shs
• Market Capitalization: $3.60 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 9/20/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:AKRXQ
• CIK: N/A
• Web: www.akorn.com
• Phone: 847-279-6100
• Fax: 800-943-3694
• Employees: 2,191
• Year Founded: 1948

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $682.43 million
• Price / Sales: 0.01
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 133,451,000
• Free Float: 128,246,000
• Market Cap: $3.60 million
• Optionable: Not Optionable
• Beta: N/A